ARID1A and cancer: A recent sequencing study identified cancer‐associated inactivating ARID1A mutations in deep infiltrating endometriosis, with loss of ARID1A immunoreactivity serving as a surrogate for ARID1A inactivating mutations using the HPA005456 antibody 35.